Skip to content
About Us
Our Company
Our Team
Directors
Contact
Our Science
VAAST Platform
Mucosal Immunity
Platform Difference
Pipeline
COVID-19
Norovirus
Influenza
HPV
Publications
Investors
Careers
Vaxart Guiding Principles
Benefits
Open Positions
Category:
Uncategorized
Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
August 6, 2026
Read More
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
August 5, 2026
Read More
Vaxart Announces Results of Annual Meeting of Stockholders
July 17, 2026
Read More
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
July 6, 2026
Read More
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
July 1, 2026
Read More
Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
June 26, 2026
Read More
Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
June 16, 2026
Read More
Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
June 8, 2026
Read More
Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders
June 1, 2026
Read More
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
May 19, 2026
Read More
1
2
3
…
5
Next Page
